Neuberger Berman Group
BMY.RT

Neuberger Berman Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Neuberger Berman Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-256,428
Closed -$177K – 1866
2020
Q4 		$177K Sell
256,428
-167,724
-40% -$357K ﹤0.01% 1640
2020
Q3 		$955K Sell
424,152
-302,616
-42% -$864K ﹤0.01% 1229
2020
Q2 		$2.6M Buy
726,768
+465,429
+178% +$1.68M ﹤0.01% 959
2020
Q1 		$993K Sell
261,339
-381,299
-59% -$1.26M ﹤0.01% 1096
2019
Q4 		$1.94M Buy
+642,638
New +$1.67M ﹤0.01% 1035

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Neuberger Berman Group's BMY.RT Position: Q1 2021 in Review

Neuberger Berman Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 256,428 shares — an estimated $177K sold.

Neuberger Berman Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2.6M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Neuberger Berman Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Neuberger Berman Group sold 256,428 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $177K.
  • Neuberger Berman Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Neuberger Berman Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.6M in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Neuberger Berman Group's 13F filing for Q1 2021, filed 13 May 2021.